Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors

Journal of Urology

Volumn 168, Issue 2, 2002, Pages 465-469

  Eissa, Sanaa ^a,b   Swellam, Menha ^b   Sadek, M ^a,b   Mourad, M Sherif ^b   Ahmady, O El ^a,b   Khalifa, A ^a,b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NONE

Author keywords

Antigens; Bladder neoplasms; Schistosomiasis; Tumor markers, biological

Indexed keywords

CELL NUCLEUS MATRIX PROTEIN 22; CREATININE; FIBRONECTIN; NUCLEAR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; CYSTOSCOPY; DEVICE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHISTOSOMIASIS; URINARY TRACT DISEASE; URINE CYTOLOGY; URODYNAMICS;

EID: 0036077918     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64659-9     Document Type: Article

References (35)

1. Bladder cancer-associated nuclear matrix proteins
2. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
3. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma
4. New methods for detection of bladder cancer
5. Telomerase in urological malignancy
6. Comparison of the monoclonal UBC-ELISA test and the NMP22-ELISA test for the detection of urothelial cell carcinoma of the bladder
7. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder
8. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder
9. Clearing and release of basement membrane proteins from substrates by metastatic tumor cell variants
10. Significance of tissue laminin P(1) elastase and fibronectin levels in transitional cell carcinoma of the bladder
11. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
12. Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymatic assay with domain-specific monoclonal antibodies
13. Basic principles of ROC analysis
14. Comparative evaluation of the BTA stat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors
15. Soluble forms of the adhesion molecule E-cadherin in urine
16. Clinical evaluation of urinary and serum carcinoembryonic antigen in bladder cancer
17. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
18. Improved detection of recurrent bladder cancer using the Bard BTA stat test
19. Identification of a nuclear protein matrix
20. Nuclear matrix and the regulation of gene expression: Tissue specificity
21. Bladder cancer-associated nuclear matrix proteins
22. Utilization of nuclear matrix proteins for cancer diagnosis
23. Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer
24. Tumor invasion and the extracellular matrix
25. Evaluation of two new urinary tumor markers: Bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer
26. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: Comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder
27. Sensitivity and specificity of NMP22, telomerase, and BTA in detection of human bladder cancer
28. Urinary nuclear matrix protein as a tumor marker for transitional cell carcinoma of the urinary tract
29. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder
30. Analysis of the performance of pathologists in the grading of bladder tumors
31. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
32. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer
33. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer